본문으로 건너뛰기
← 뒤로

Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer.

Cancer treatment reviews 2026 Vol.142() p. 103061

Lin C, Hadfield MJ, Rathore A, Pinho-Schwermann M, Zhang S, Lu S, Hollander PD, Mani SA, Seyhan AA, Santopietro A, Mega A, Cheng L, El-Deiry WS, Carneiro BA

📝 환자 설명용 한 줄

Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Lin C, Hadfield MJ, et al. (2026). Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer.. Cancer treatment reviews, 142, 103061. https://doi.org/10.1016/j.ctrv.2025.103061
MLA Lin C, et al.. "Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer.." Cancer treatment reviews, vol. 142, 2026, pp. 103061.
PMID 41330005

Abstract

Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality. Despite the efficacy of androgen deprivation therapy (ADT), patients with advanced PCa eventually progress to a lethal castration-resistant disease state. Cellular senescence represents a stable growth arrest induced by stress signaling cascades or cancer therapeutics, and escape from a senescent state may be implicated in the development of castration resistance. We discuss the mechanisms promoting cellular senescence in PCa and its contribution to therapeutic resistance to ADT, PARP inhibitors, chemotherapy, and radiation. We also summarize the potential of senolytic and senomorphic therapies in targeting senescent prostate cancer cells in the setting of therapy-induced senescence.

MeSH Terms

Humans; Male; Cellular Senescence; Drug Resistance, Neoplasm; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Androgen Antagonists; Poly(ADP-ribose) Polymerase Inhibitors

같은 제1저자의 인용 많은 논문 (5)